New shot aims to block tetanus after cuts and wounds

NCT ID NCT07347938

Recruiting now Prevention Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This study tests a new medicine called siltartoxatug to prevent tetanus in people who have been injured. About 6,000 adults in China will receive either the new drug or a standard tetanus shot. Researchers will check how well each treatment prevents tetanus over 90 days and monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: siltartoxatug injection
What this could lead to: If successful, siltartoxatug could offer a new, effective option to prevent tetanus after injuries, potentially with fewer side effects than current treatments.
What could go wrong: This is a Phase 4 study, so the drug is already approved, but it is still being tested in a large real-world setting. There is always a risk of unexpected side effects or that it may not be as effective as existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TETANUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

tetanus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TETANUS

Contacts and locations

Locations

The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.